Mitochondrial Research

SS-31 (Elamipretide)

6.0/10

BioHarmony verdict

Worth trying

SS-31 (elamipretide) is a mitochondria-targeting tetrapeptide that binds cardiolipin. Karaa 2023 found no broad PMM benefit in MMPOWER-3, while FDA granted accelerated Forzinity approval for Barth syndrome in patients weighing at least 30 kg.

Read full report

What is SS-31 (Elamipretide)?

SS-31, now known clinically as elamipretide and marketed as Forzinity for Barth syndrome, is a mitochondria-targeting tetrapeptide designed to bind cardiolipin in the inner mitochondrial membrane. Cardiolipin helps organize mitochondrial cristae, the folds where electron transport chain complexes sit and ATP is produced. Birk 2013 showed SS-31 interacting with cardiolipin in ischemic mitochondria, while Szeto 2014 framed the compound as the lead cardiolipin-protective peptide in the Szeto-Schiller class.

From the BioHarmony report, reviewed 2026-09-08.

How it is thought to work

Binds cardiolipin on the inner mitochondrial membrane, supports cristae architecture and electron transport chain supercomplex organization, and reduces mitochondrial ROS leak.

Safety watch-outs

  • Injection-site infection
  • New severe weakness or muscle pain

Full risk profile in the BioHarmony report.

Dosing as published

No approved-label or study protocol is recorded for SS-31 (Elamipretide) yet.

More reported protocols

Members

Members can compare additional reported doses, schedules, and preparation notes.

Educator coverage (6)

Attributed viewpoints, separate from primary research.

Trust & sourcing

US approvalFDA-approved product exists
CompoundingApproved product exists; compounded copies are not FDA approved
Last checked2026-07-13
Next review2026-10-11 (overdue, details paused)

Primary sources

Sources are still being reviewed for this compound.

Free guide

The Ultimate Peptides Guide

Spot stronger candidates, weak evidence, and seller red flags before you buy.

Free. Includes evidence and regulatory updates. Unsubscribe anytime.